Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Dabigatran pro doplňkovou léčbu bakteriémie Staphylococcus aureus (DABI-SNAP)

Dabigatran pro doplňkovou léčbu bakteriémie Staphylococcus Aureus: vnořená randomizovaná kontrolovaná studie DABI-SNAP

This is an open-label randomized controlled trial which will enroll patients with S. aureus bacteremia who are already taking oral anticoagulant medications (apixaban, edoxaban, or rivaroxaban) for an approved indication (stroke prevention in atrial fibrillation, prevention or treatment of venous thromboembolism). We will randomize patients to continue their existing medication or change to another medication (dabigatran) which is approved for the original indication.

Dabigatran is approved in many countries for the treatment or prevention of venous thromboembolism or preventing stroke in atrial fibrillation. Unlike the other medications listed above, dabigatran seems to have activity against S. aureus in the test tube, in animal models, and in a smaller randomized controlled trial. We wish to determine if changing to dabigatran will improve outcomes in S. aureus bacteremia in people who otherwise would have a reason to be taking it.

This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119).

If positive, this study will support a second RCT in people who do not currently have an indication for anticoagulation.

Přehled studie

Postavení

Nábor

Podmínky

Intervence / Léčba

Typ studie

Intervenční

Zápis (Odhadovaný)

300

Fáze

  • Fáze 4

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

    • Newfoundland and Labrador
      • St. John's, Newfoundland and Labrador, Kanada, NL A1C 5B8
        • Nábor
        • NL and Labrador Health Services- St. Clare's Mercy Hospital
        • Vrchní vyšetřovatel:
          • Peter Daley, MD
        • Kontakt:
      • St. John's, Newfoundland and Labrador, Kanada, A1B 3V6
        • Nábor
        • NL and Labrador Health Services- Health Sciences Centre
        • Vrchní vyšetřovatel:
          • Peter Daley, MD
        • Kontakt:
    • Quebec
      • Montreal, Quebec, Kanada, H4A3S1
        • Nábor
        • McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)
        • Vrchní vyšetřovatel:
          • Emily G McDonald, MD MSc
        • Vrchní vyšetřovatel:
          • Todd C Lee, MD MPH FIDSA
        • Dílčí vyšetřovatel:
          • Alexander Lawandi, MD MSc
        • Dílčí vyšetřovatel:
          • Matthew P. Cheng, MD SM
        • Dílčí vyšetřovatel:
          • Patrick Lawler, MD MPH
        • Kontakt:

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

The participant must meet all inclusion and exclusion criteria for the SNAP Platform (NCT05137119) and also the following inclusion and exclusion criteria:

Inclusion Criteria:

  • Patient is taking (or will imminently start taking) an oral Xa inhibitor (e.g., apixaban, edoxaban, rivaroxaban) for: stroke prevention in atrial fibrillation, treatment or secondary prevention of deep venous thrombosis or pulmonary embolism, prevention of VTE in patients who have undergone elective total hip or total knee replacement surgery provided there are 30 or more days of planned treatment remaining at the time of enrolment.

Exclusion Criteria:

  • Active bleeding as determine by the site investigator after discussion with the treating team (patient may remain eligible for up to 120 hours from platform entry if condition is resolved and antithrombotic therapy is resumed)
  • Anticipated major cardiac surgery, neurosurgery, or spine surgery within the next 3 days
  • Known pregnancy (with testing available for women with childbearing potential)
  • Known use of dabigatran within last month
  • Allergy to dabigatran
  • Concomitant use of amiodarone, ketoconazole, rifampin, verapamil, clopidogrel, prasugrel, or ticagrelor
  • eGFR < 30mL/minute calculated by Cockcroft-Gault equation using adjusted weight [patient may remain eligible for up to 120 hours from platform entry if acute kidney injury is resolved such that antithrombotic therapy can be safely resumed/prescribed]
  • Off label use (e.g., metallic mechanical heart valve, left ventricular thrombus, antiphospholipid antibody syndrome)

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Singl

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Change to Dabigatran

Patients will have their anticoagulation changed to dabigatran at the monograph approved dose for the indication, bleeding risk, and renal function.

Patients will be assigned to change to dabigatran at the monograph approved dose for their indication, bleeding risk, and renal function.

Aktivní komparátor: Continue current anticoagulant

Patients will continue their currently prescribed apixaban, edoxaban, or rivaroxaban

Patients will continue taking their currently prescribed apixaban, edoxaban, or rivaroxaban

Patients will continue taking their currently prescribed apixaban, edoxaban, or rivaroxaban

Patients will continue taking their currently prescribed apixaban, edoxaban, or rivaroxaban

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Desirability of Outcome Ranking (DOOR)
Časové okno: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)

Desirability of Outcome Ranking (DOOR) - an ordinal outcome with 5 levels defined:

Rank 1 - Alive without complication Rank 2 - Alive with 1 complication Rank 3 - Alive with 2 complications Rank 4 - Alive with 3 complications Rank 5 - Dead

Complications include:

  1. Clinical failure: Absence of resolution of clinical signs and symptoms of S. aureus bacteremia such that no additional antibiotic therapy is required or anticipated.
  2. Infectious Complications: Including new endocarditis; new evidence of other deep metastatic foci (e.g., osteomyelitis or deep abscess); relapse of MRSA bacteremia after a patient has sterilized their initial blood cultures; readmission for subsequent care of S. aureus bacteremia; need for unplanned source control procedures
  3. Serious adverse drug event (Common Terminology Criteria class 4) due to study drug OR adverse drug event (classes 1-3) leading to discontinuation of the study drug
Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Serious Adverse Event or Adverse Event Leading to Discontinuation
Časové okno: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)

Defined as a serious adverse drug event (Common Terminology Criteria for Adverse Events (CTCAE) class 4) presumed due to study drug OR adverse drug event (CTCAE classes 1-3) leading to discontinuation of the study drug

Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)
All cause mortality
Časové okno: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)

Death from any cause

Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)
Infectious Complications
Časové okno: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)

Defined as change in therapy for inadequate clinical response; new endocarditis; new evidence of other deep metastatic foci (e.g., osteomyelitis or deep abscess); relapse of MRSA bacteremia after a patient has sterilized their initial blood cultures; readmission for subsequent care of S. aureus bacteremia; need for unplanned source control procedures. New implies that the complication was not suspected at enrollment and is not a function of delay to diagnostic testing.

Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)
Clinically relevant major bleeding
Časové okno: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)

This will be defined according to the criteria of the International Society on Thrombosis and Haemostasis as one or more of the following: fatal bleeding; symptomatic bleeding in a critical area or organ (including hemorrhagic stroke); bleeding that causes a fall in hemoglobin level of ≥20 g/L; or bleeding that requires a transfusion of 2 or more units of whole blood or red cells. For bleeds into non-critical areas, we will also record the site of bleeding.

Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)
Clinically relevant venous thromboembolic events
Časové okno: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)

This will be defined as an acute objectively confirmed deep vein thrombosis (upper extremity, lower extremity, other such as portal vein, cerebral vein, splanchnic vein) and/or segment or proximal pulmonary embolism, which is symptomatic and/or necessitates specific treatment. Below knee DVT and superficial thrombophlebitis are not included. Pulmonary embolism needs to be, segmental or proximal. Subsegmental pulmonary embolisms are not included as they have poor interrater reliability and may represent artefact in up to 50% of cases.

Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)
Clinically relevant stroke
Časové okno: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)

Stroke is defined as the acute onset of focal neurological dysfunction caused by brain, spinal cord, or retinal vascular injury because of infarction (ischemia). Ideally, at least one of the following should be present to confirm the diagnosis of stroke: confirmation by neurology, stroke specialist, or neurosurgical specialist, brain imaging (e.g., CT scan, MRI scan, or cerebral vessel angiography compatible with acute ischemia). If the acute focal signs represent a worsening of a previous deficit, these signs must persist for more than 24 hours and be accompanied by an appropriate new MRI or CT scan finding. In the absence of neuroimaging, a staff neurologist consult which makes the diagnosis of stroke will be considered.

Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)
Clinically relevant acute myocardial infarction
Časové okno: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)

Patients with S. aureus bacteremia often have substantial physiological stresses which can be associated with rises in cardiac troponin (demand ischemia). For the purposes of this outcome, acute myocardial infarction is captured as a type 1 myocardial infarction: detection of rise and/or fall of cardiac biomarkers with at least one value above the 99th percentile of the upper reference limit together with evidence of myocardial ischemia. For the purposes of this pragmatic trial, such a myocardial infarction will be inferred from the opinions of the staff cardiologist, intensivist, or general internal medicine specialist. The peak troponin value will be recorded, and a redacted copy of the relevant consultant's note and ECGs will be uploaded for audit.

Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)
Clinically relevant arterial thromboembolic event
Časové okno: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)

Clinical history compatible with sudden worsening of end organ or limb perfusion and confirmation by imaging (e.g., CT angiography, arterial doppler) or need for urgent surgery or thrombolysis.

Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)
Clinical failure
Časové okno: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)

Defined as the absence of resolution of clinical signs and symptoms of S. aureus bacteremia such that no additional antibiotic therapy is required or anticipated for its treatment.

Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Spolupracovníci

Vyšetřovatelé

  • Vrchní vyšetřovatel: Emily G McDonald, MD MSC, Research Institute of the McGill University Health Centre

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Obecné publikace

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

15. ledna 2026

Primární dokončení (Odhadovaný)

1. ledna 2030

Dokončení studie (Odhadovaný)

1. ledna 2030

Termíny zápisu do studia

První předloženo

18. října 2024

První předloženo, které splnilo kritéria kontroly kvality

18. října 2024

První zveřejněno (Aktuální)

21. října 2024

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

24. září 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

21. září 2026

Naposledy ověřeno

1. září 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • 2025-10900
  • 500464 (Jiné číslo grantu/financování: Canadian Institutes of Health Research)
  • 2025 (Grant/smlouva NIH USA)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

This statement supersedes any such statement in NCT05137119.

For DABI-SNAP, we will provide deidentified individual patient data required to replicate the main manuscript's tables and analyses.

Časový rámec sdílení IPD

Starting 1 year after the publication of the main trial manuscript for up to 7 years.

Kritéria přístupu pro sdílení IPD

Researchers will need to request the data from the corresponding author of the main trial manuscript with an accompanying written proposal for the secondary analysis. Once approved by the trial steering committee, a data sharing agreement will be signed by the responsible parties and the deidentified data set will be provided via a secure transmission.

Typ podpůrných informací pro sdílení IPD

  • PROTOKOL STUDY
  • MÍZA
  • ICF
  • ANALYTIC_CODE

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .